341 related articles for article (PubMed ID: 36556070)
1. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.
Choi JH; Paik WH
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556070
[TBL] [Abstract][Full Text] [Related]
2. Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?
Gao H; Wang W; Yu X; Liu L
Crit Rev Oncol Hematol; 2021 Nov; 167():103493. PubMed ID: 34653597
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.
Lam AK; Ishida H
Histol Histopathol; 2021 Apr; 36(4):367-382. PubMed ID: 33305819
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.
Lee L; Ito T; Jensen RT
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1029-1050. PubMed ID: 31738624
[No Abstract] [Full Text] [Related]
5. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.
Aysal A; Agalar C; Egeli T; Unek T; Oztop I; Obuz F; Sagol O
Endocr Pathol; 2021 Dec; 32(4):461-472. PubMed ID: 34283399
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
Yan J; Yu S; Jia C; Li M; Chen J
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
[TBL] [Abstract][Full Text] [Related]
8. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
Jiang R; Hong X; Zhao Y; Wu W
Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms.
Smolkova B; Kataki A; Earl J; Ruz-Caracuel I; Cihova M; Urbanova M; Buocikova V; Tamargo S; Rovite V; Niedra H; Schrader J; Kohl Y
Crit Rev Oncol Hematol; 2022 Dec; 180():103865. PubMed ID: 36334880
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based study.
Guo N; Liang Z; Xiong LJ
Medicine (Baltimore); 2022 Oct; 101(41):e31019. PubMed ID: 36254020
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.
Lee L; Igarashi H; Fujimori N; Hijioka M; Kawabe K; Oda Y; Jensen RT; Ito T
Jpn J Clin Oncol; 2015 Dec; 45(12):1131-8. PubMed ID: 26378090
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).
Ciobanu OA; Martin S; Fica S
Exp Ther Med; 2021 Dec; 22(6):1479. PubMed ID: 34765020
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
16. Neuroendocrine Neoplasms of the Pancreas: Diagnostic Challenges and Practical Approach.
Alipour Z; Sweeney JR; Zhang Q; Yang Z
Adv Anat Pathol; 2023 Jan; 30(1):58-68. PubMed ID: 36136369
[TBL] [Abstract][Full Text] [Related]
17. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.
Li TT; Qiu F; Qian ZR; Wan J; Qi XK; Wu BY
World J Gastroenterol; 2014 Jan; 20(1):118-25. PubMed ID: 24415864
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
20. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Sigel CS
Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
